Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program

Ghadeer Hasan, Elizabeth D. Ferucci, Jill P. Buyon, H. Michael Belmont, Jane E. Salmon, Anca Askanase, Joan M. Bathon, Laura Geraldino-Pardilla, Yousaf Ali, Ellen M. Ginzler, Chaim Putterman, Caroline Gordon, Charles G. Helmick, Hilary Parton, Peter M. Izmirly

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objective: Epidemiological data for MCTD are limited. Leveraging data from the Manhattan Lupus Surveillance Program (MLSP), a racially/ethnically diverse population-based registry of cases with SLE and related diseases including MCTD, we provide estimates of the prevalence and incidence of MCTD. Methods: MLSP cases were identified from rheumatologists, hospitals and population databases using a variety of International Classification of Diseases, Ninth Revision codes. MCTD was defined as one of the following: fulfilment of our modified Alarcon-Segovia and Kahn criteria, which required a positive RNP antibody and the presence of synovitis, myositis and RP; a diagnosis of MCTD and no other diagnosis of another CTD; and a diagnosis of MCTD regardless of another CTD diagnosis. Results: Overall, 258 (7.7%) cases met a definition of MCTD. Using our modified Alarcon-Segovia and Kahn criteria for MCTD, the age-Adjusted prevalence was 1.28 (95% CI 0.72, 2.09) per 100 000. Using our definition of a diagnosis of MCTD and no other diagnosis of another CTD yielded an age-Adjusted prevalence and incidence of MCTD of 2.98 (95% CI 2.10, 4.11) per 100 000 and 0.39 (95% CI 0.22, 0.64) per 100 000, respectively. The age-Adjusted prevalence and incidence were highest using a diagnosis of MCTD regardless of other CTD diagnoses and were 16.22 (95% CI 14.00, 18.43) per 100 000 and 1.90 (95% CI 1.49, 2.39) per 100 000, respectively. Conclusions: The MLSP provided estimates for the prevalence and incidence of MCTD in a diverse population. The variation in estimates using different case definitions is reflective of the challenge of defining MCTD in epidemiologic studies.

Original languageEnglish
Pages (from-to)2845-2849
Number of pages5
JournalRheumatology
Volume62
Issue number8
DOIs
StatePublished - 1 Aug 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.

Funding

Disclosure statement: C.G. received consulting fees from the CDC, AbbVie, AstraZeneca, MGP, Sanofi and UCB and grants from UCB and Sandwell and West Birmingham Hospitals NHS Trust. P.M.I. received consulting fees from GlaxoSmithKline and Momenta/Janssen. G.H., E.D.F., J.P.B., H.M.B., J.E.S., A.A., J.M.B., L.G.-P., Y.A., E.M.G., C.P., C.G.H. and H.P. have nothing to declare. Acknowledgements This work was funded by a grant (U58/DP002827) from the CDC. This publication was supported by the CDC as part of a financial assistance award totaling $5.3 million with 100% funded by CDC/Department of Health and Human Services (HHS). Cooperative agreements between the NYC DOHMH and New York University School of Medicine provided support for this analysis.

FundersFunder number
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
Sanofi
AbbVie
Sandwell and West Birmingham Hospitals NHS Trust
School of Public Health, University of California Berkeley

    Keywords

    • MCTD
    • epidemiology
    • incidence
    • prevalence

    Fingerprint

    Dive into the research topics of 'Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program'. Together they form a unique fingerprint.

    Cite this